From the Division of Plastic and Reconstructive Surgery, University of Montreal Hospital Center.
University of Montreal.
Plast Reconstr Surg. 2024 May 1;153(5):864e-872e. doi: 10.1097/PRS.0000000000010823. Epub 2023 Jun 19.
Breast reconstruction following nipple-sparing mastectomy (NSM) in patients with large or ptotic breasts remains challenging because of the risk of ischemic complications and the difficulty in managing the redundant skin envelope. Staged mastopexy or breast reduction before the mastectomy/reconstruction has been shown to decrease the risk of complications and improve clinical outcomes.
A retrospective analysis was conducted of patients with a genetic predisposition to breast cancer who underwent staged breast reduction/mastopexy before NSM and reconstruction in the authors' institution. In patients with in situ disease or invasive cancer, the first stage consisted of lumpectomy and oncoplastic reduction/mastopexy. Breast reconstruction at the second stage was performed with free abdominal flaps or breast implants and acellular dermal matrix. Data regarding the ischemic complications were recorded.
In total, 47 patients (84 breasts) underwent this staged approach. All patients had a genetic predisposition to breast cancer. The time interval between the two stages was 11.5 months (range, 1.3 to 23.6 months). Twelve breasts (14.3%) were reconstructed with free abdominal flaps, six (7.1%) with tissue expanders, and 66 (78.6%) with permanent subpectoral implants and acellular dermal matrix. There was one case of postoperative superficial nipple-areola complex epidermolysis (1.2%), and two cases of partial mastectomy skin flap necrosis (2.4%). The mean follow-up time after completion of reconstruction was 8.3 months.
Mastopexy or breast reduction before NSM and reconstruction is a safe procedure with a low risk of ischemic complications.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.
对于乳房较大或下垂的患者,行保留乳头乳晕的乳房切除术(NSM)后进行乳房重建仍然具有挑战性,因为存在缺血性并发症的风险,且乳房多余皮肤的处理较为困难。在乳房切除术/重建之前分期行乳房悬吊术或乳房缩小术,已被证实可降低并发症风险并改善临床结局。
对在本机构行分期乳房缩小/悬吊术,随后行 NSM 和重建的具有乳腺癌遗传易感性的患者进行回顾性分析。对于原位癌或浸润性癌患者,第一阶段为保乳术和肿瘤整形缩小/悬吊术。第二期行游离腹部皮瓣或乳房植入物和脱细胞真皮基质乳房重建。记录缺血性并发症的数据。
共 47 例(84 侧乳房)患者接受了这种分期方法。所有患者均具有乳腺癌遗传易感性。两阶段之间的时间间隔为 11.5 个月(范围,1.3~23.6 个月)。12 侧乳房(14.3%)采用游离腹部皮瓣重建,6 侧(7.1%)采用组织扩张器,66 侧(78.6%)采用永久性胸肌下植入物和脱细胞真皮基质。术后发生 1 例(1.2%)乳头乳晕复合体浅层表皮剥脱,2 例(2.4%)部分乳房皮瓣坏死。重建完成后平均随访 8.3 个月。
NSM 和重建之前行乳房悬吊术或乳房缩小术是一种安全的方法,缺血性并发症风险低。
临床问题/证据水平:治疗性,IV。